Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  DRG Market Assessment Reports

Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia | Current Treatment: Physician Insights | US | 2019

Login to access report north_east
Contact sales account_box

Non-Hodgkin’s lymphoma (NHL) comprises a heterogeneous group of hematological malignancies that can be broadly classified into indolent and aggressive subtypes. The treatment algorithm for NHL continues to evolve rapidly as existing drug labels are expanded and new therapies are added to the armamentarium. Over the past two years, new market entrants include PI3K inhibitor Copiktra (Verastem), BTK inhibitor Calquence (AstraZeneca), and the anti-CD19 CAR T-cell therapies Kymriah (Novartis) and Yescarta (Gilead / Kite Pharma). These novel therapies will command high prices, but their commercial success will also be determined based on how well they are adopted into clinical practice.

Questions Answered

  • What is the uptake of recent market entrants in the United States, such as Kymriah, Yescarta, Aliqopa, and Calquence, according to surveyed hematologist-oncologists?
  • How do drug-treatment rates vary across NHL / CLL subtypes, according to line of therapy?
  • What is the patient share of key therapies and regimens used to treat newly diagnosed and relapsed/refractory NHL / CLL subtypes?
  • What are the key drivers and obstacles determining current prescribing patterns in NHL / CLL?

Product Description

Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.

Markets covered: United States.

Primary research: Survey of 101 U.S. hematologist-oncologists.

Key Drugs Covered: Aliqopa, Arzerra, Calquence, Copiktra, Gazyva, Imbruvica, Kymriah, Revlimid, Rituxan / Rituxan Hycela, Velcade, Venclexta, Yescarta, Zydelig.

Key Subtypes Covered: Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and mantle cell lymphoma (MCL).

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Asthma – Unmet Need – Unmet Need – Severe Asthma (US/EU)
Several effective anti-inflammatory agents and bronchodilators are available for controlling patients’ mild or moderate asthma. However, despite the availability of LAMAs (e.g., Boehringer…
north_east
Report
Systemic Lupus Erythematosus – Current Treatment – Treatment Algorithms: Claims Data Analysis – Systemic Lupus Erythematosus (US)
Systemic lupus erythematosus (SLE) is an autoimmune disease that affects multiple organ systems of the body. Symptoms range from general malaise to serious renal and CNS manifestations…
north_east
Report
Chronic Kidney Disease – Current Treatment – Treatment Algorithms: Claims Data Analysis – Chronic Kidney Disease (US)
Chronic kidney disease (CKD) is caused by structural or functional abnormalities in the kidney that impair its ability to filter blood. The CKD drug market primarily comprises therapies, which are…
north_east
Report
Multiple Sclerosis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Multiple Sclerosis (US)
The multiple sclerosis (MS) therapy market comprises more than 20 immunomodulatory disease-modifying therapies (DMTs), and more are in the pipeline. A variety of drug classes each hold a niche…
north_east
Report
Asthma – Access & Reimbursement – Access & Reimbursement – Asthma (US)
The dynamics within the LABA/ICS FDC, LAMA, LABA/LAMA/ICS FDC, and biological drug classes will continue to shape the U.S. asthma market. The dominance of branded LABA/ICS FDCs (e.g., GSK’s…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east